TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 58 filers reported holding TCR2 THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,050 | +50.2% | 700 | 0.0% | 0.00% | – |
| Q4 2022 | $699 | -30.1% | 700 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | -50.0% | 700 | 0.0% | 0.00% | – |
| Q2 2022 | $2,000 | 0.0% | 700 | 0.0% | 0.00% | – |
| Q1 2022 | $2,000 | -50.0% | 700 | -17.6% | 0.00% | – |
| Q4 2021 | $4,000 | -89.5% | 850 | -81.1% | 0.00% | – |
| Q3 2021 | $38,000 | -89.9% | 4,506 | -80.3% | 0.00% | -100.0% |
| Q2 2021 | $375,000 | -25.3% | 22,874 | +0.7% | 0.00% | 0.0% |
| Q1 2021 | $502,000 | -24.3% | 22,724 | +6.1% | 0.00% | 0.0% |
| Q4 2020 | $663,000 | +4635.7% | 21,415 | +2959.3% | 0.00% | – |
| Q3 2020 | $14,000 | +27.3% | 700 | 0.0% | 0.00% | – |
| Q2 2020 | $11,000 | +120.0% | 700 | 0.0% | 0.00% | – |
| Q1 2020 | $5,000 | -16.7% | 700 | +75.0% | 0.00% | – |
| Q4 2019 | $6,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q3 2019 | $6,000 | – | 400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
| Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
| Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
| Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
| PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
| Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
| MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
| Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |